Enhanced ultrasound detection with temperature-dependent contrast agents

• US 7,179,449 B2
• Filed: 01/30/2001
• Issued: 02/20/2007
• Est. Priority Date: 01/30/2001
• Status: Expired due to Fees

• Current Assignee: Barnes-Jewish Hospital (BJC Health System)
• Original Assignee: Barnes-Jewish Hospital (BJC Health System)
• Inventors: Lanza, Gregory M., Wickline, Samuel A., Hall, Christopher S.
• Primary Examiner(s): Wang; Shengjun
• Application Number:
  US09/774,278
• Publication Number:
  US 20020102216A1
• Time in Patent Office: 2,212 Days
• Field of Search: 424/9.321, 424/9.5, 424/9.51, 424/9.52, 424/450, 514/937, 514/938
• US Class Current: 424/9.321
• CPC Class Codes: A61K 49/223 Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
• CPC Class Codes: A61K 49/226 Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels

Abstract

Methods and devices for enhanced ultrasound detection based upon changing temperature and ultrasound reflectivity of a temperature-dependent contrast agent bound to an ultrasound target are disclosed. The methods and devices can be used for enhanced imaging alone or in conjunction with drug delivery, with therapeutic approaches such as hyperthermia or cryotherapy or with other imaging modalities.

Claims

1. A method for comparing acoustic reflectivity of a target for ultrasound imaging at a lower and a higher temperature, the method comprising

(a) measuring reflectivity prior to raising the temperature of liquid nanoparticles bound to a target;

(b) raising the temperature of the liquid nanoparticles bound to said target sufficiently to produce a measurable enhancement in acoustic reflectivity of the target;

(c) measuring reflectivity after raising the temperature of the bound liquid nanoparticles; and

(d) determining the change in reflectivity of the bound liquid nanoparticles after raising the temperature compared to reflectivity prior to raising the temperature,

wherein said nanoparticles comprise at least one fluorocarbon,

said nanoparticles having been administered to said target in a non-gaseous emulsion, and wherein said nanoparticles are maintained in the liquid state during all of steps (a)–

(c).

2. The method according to claim 1 wherein the fluorocarbon is perfluorooctane.

3. The method according to claim 1 wherein the nanoparticles comprise at least one liquid fluorocarbon encapsulated with at least one lipid surfactant which comprises at least one ligand that binds to said target.

4. The method according to claim 1 wherein the emulsion further comprises a biologically active agent.

5. The method according to claim 1 wherein raising the temperature comprises providing the target with ultrasound or electromagnetic energy or a combination thereof, sufficient to raise the temperature of said nanoparticles, so as to enhance acoustic reflectivity.

6. The method according to claim 1 wherein changing the temperature comprises changing the temperature of the bound nanoparticles by at least 5°

C.

7. The method of claim 1 wherein the target resides in a mammalian subject.

8. The method of claim 1 wherein said nanoparticles comprise at least one liquid fluorocarbon encapsulated with at least one lipid surfactant.

9. The method according to claim 3 wherein the ligand is a polypeptide, a peptidomimetic, a polysaccharide, a lipid, or a nucleic acid.

10. The method according to claim 9 wherein the polypeptide is at least a portion of an antibody.

11. The method of claim 7 wherein said subject is human.

12. A method for obtaining an image resulting from enhanced acoustic reflectivity of a target for ultrasound imaging, the method comprising

(a) changing the temperature of liquid nanoparticles bound to said target sufficiently to produce a measurable enhancement of acoustic reflectivity of the target, and

(b) obtaining an ultrasound image of said target, bound to said liquid nanoparticles,

wherein said nanoparticles comprise at least one fluorocarbon, said nanoparticles having been administered to said target in a non-gaseous emulsion;

and

wherein said nanoparticles are maintained in the liquid state during both of steps (a) and (b).

13. The method according to claim 12 wherein the fluorocarbon is perfluorooctane.

14. The method according to claim 12 wherein the nanoparticles comprise at least one perfluorocarbon encapsulated with at least one lipid surfactant which comprises at least one ligand that binds to said target.

15. The method according to claim 12 wherein the emulsion further comprises a biologically active agent.

16. The method according to claim 12 wherein changing the temperature comprises providing the target with ultrasound or electromagnetic energy or a combination thereof, sufficient to raise the temperature of said nanoparticles, so as to enhance acoustic reflectivity.

17. The method according to claim 12 wherein raising the temperature comprises raising the temperature of the bound nanoparticles by at least 5°

C.

18. The method of claim 12 wherein the target resides in a mammalian subject.

19. The method of claim 18 wherein said subject is human.

20. The method of claim 12 wherein said nanoparticles comprise at least one liquid fluorocarbon encapsulated with at least one lipid surfactant.

21. The method according to claim 14 wherein the ligand is a polypeptide, a peptidomimetic, a polysaccharide, a lipid, or a nucleic acid.

22. The method according to claim 21 wherein the polypeptide is at least a portion of an antibody.